Universidad Peruana Cayetano Heredia
Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Marcos, L. | |
| dc.contributor.author | Maco, V. | |
| dc.contributor.author | Terashima, A. | |
| dc.date.accessioned | 2021-10-04T23:01:01Z | |
| dc.date.available | 2021-10-04T23:01:01Z | |
| dc.date.issued | 2021 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/9903 | |
| dc.description.abstract | Introduction: The only drug effective against the infection caused by Fasciola hepatica or F. gigantica is triclabendazole (TCBZ), recommended by the WHO and recently approved by the FDA. Here, we describe the evolution of TCBZ regimens and the emergence of TCBZ failure to Fasciola infection. Areas covered: The present review focuses on the evidence of TCBZ for the treatment of fascioliasis. For acute fascioliasis, there is a lack of studies to measure the presence of eggs of Fasciola in stool samples on the follow-up after initial TCBZ treatment. For chronic fascioliasis, WHO recommends a single oral dose of TCBZ 10 mg/kg whereas CDC recommends two doses of TCBZ 10 mg/kg 12 h apart. Incremental number of treatment failures have been documented worldwide. There are currently no therapeutic alternatives for the treatment of fascioliasis in humans. Expert opinion: Most cases of human fascioliasis are successfully treated with TCBZ, but some continue excreting eggs in the stools despite 1–2 standard of care regimens of TCBZ. A precise regimen is unclear for those patients who fail the initial treatment with TCBZ. Further clinical trials are needed to address the possible TCBZ emerging resistance | en_US |
| dc.language.iso | eng | |
| dc.publisher | Taylor and Francis | |
| dc.relation.ispartofseries | Expert Review of Anti-Infective Therapy | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | clinical trials | en_US |
| dc.subject | efficacy | en_US |
| dc.subject | Fasciola | en_US |
| dc.subject | neglected tropical disease | en_US |
| dc.subject | resistance | en_US |
| dc.subject | treatment failure | en_US |
| dc.subject | triclabendazole | en_US |
| dc.title | Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures | en_US |
| dc.type | info:eu-repo/semantics/review | |
| dc.identifier.doi | https://doi.org/10.1080/14787210.2021.1858798 | |
| dc.relation.issn | 1744-8336 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
